MacroGenics, Inc. (NASDAQ: MGNX) is a Healthcare company (Biotechnology) with a market capitalization of $131M. The Maz Rating grades it against the other companies in its sector.
MacroGenics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.05, MacroGenics, Inc. trades at 1.2x sales and 5.2x book value. Over the last twelve months it generated about $113M of revenue and a net loss of $52M. It runs a gross margin of 4.2%, an operating margin of -70.2% and a net margin of -45.4%. It shows return on equity of -142.2%, return on invested capital of -13.6% and a free cash flow yield of -31.6%. On the balance sheet: a debt-to-equity ratio of 1.39 and a current ratio of 2.75. Over the past 52 weeks the share price ranged from $1.32 to $5.08, with a beta of 1.32.
MacroGenics, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 12 Buy, 9 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.